Postdoctoral Scholar
| Ph.D. | Biological Chemistry | 2015 | Johns Hopkins School of Medicine, Baltimore, MD |
| M.A. | Biotechnology | 2010 | Columbia University, New York, NY |
| B.Sc. | Biotechnology | 2008 | The University of Nottingham, Nottingham, UK |
| 2016-Present: | Postdoctoral Scholar, Mass Spectrometry Facility, Dept. of Pharmaceutical Chemistry, UCSF, CA |
| 2016-Present: | Compliance Manager, Molecular and Cellular Proteomics, Rockville, MD |
My research is focused on understanding cell signaling events and protein-protein interactions involved in cancer progression using discovery and targeted proteomics methods. In my role as the Editor of Manuscript Integrity for Molecular & Cellular Proteomics, I work with authors and editors to ensure manuscript compliance to the journal standard and guidelines.
Wu X, Zahari MS, Renuse S, Kelkar DS, Bharbuiya MA, Rojas PL, Stearns V, Gabrielson E, Malla P, Sukumar S, Mahajan NP, Pandey A.. The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer. Oncotarget, 8(2),2971-2983 (2017). [Pubmed]
Wu X, Zahari MS, Ma B, Liu R, Renuse S, Sahasrabuddhe NA, Chen L, Chaerkady R, Kim MS, Zhong J, Jelinek C, Barbhuiya MA, Leal-Rojas P, Yang Y, Kashyap MK, Marimuthu A, Ling M, Fackler MJ, Merino V, Zhang Z, Zahnow CA, Gabrielson E, Stearns V, Roa JC, Sukumar S, Gill PS, Pandey A. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways. Oncotarget, 6(30), 29143-29160 (2015). [Pubmed]
Zahari MS, Wu X, Pinto SM, Nirujogi RS, Kim MS, Fetics B, Philip M, Barnes SR, Godfrey B, Gabrielson E, Nevo E, Pandey A. Phosphoproteomic profiling of tumor tissues identifies HSP27 Ser82 phosphorylation as a robust marker of early ischemia. Sci Rep., 5, 13660 (2015). [Pubmed]
Wu X, Zahari MS, Renuse S, Nirujogi RS, Kim MS, Manda SS, Stearns V, Gabrielson E, Sukumar S, Pandey A. Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer. Mol Cell Proteomics, 14(11), 2887-2900 (2015). [Pubmed]
Zahari MS, Wu X, Blair BG, Pinto SM, Nirujogi RS, Jelinek CA, Malhotra R, Kim MS, Park BH, Pandey A. Activating Mutations in PIK3CA Lead to Widespread Modulation of the Tyrosine Phosphoproteome. J Proteome Res., 14(9), 3882-3891 (2015). [Pubmed]
Blair BG, Wu X, Zahari MS, Mohseni M, Cidado J, Wong HY, Beaver JA, Cochran RL, Zabransky DJ, Croessmann S, Chu D, Toro PV, Cravero K, Pandey A, Park BH. A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations. Proteomics, 15(2-3), 318-326 (2015). [Pubmed]
Wu X, Renuse S, Sahasrabuddhe NA, Zahari MS, Chaerkady R, Kim MS, Nirujogi RS, Mohseni M, Kumar P, Raju R, Zhong J, Yang J, Neiswinger J, Jeong JS, Newman R, Powers MA, Somani BL, Gabrielson E, Sukumar S, Stearns V, Qian J, Zhu H, Vogelstein B, Park BH, Pandey A. Activation of diverse signalling pathways by oncogenic PIK3CA mutations. Nat Commun., 5, 4961 (2014). [Pubmed]
Kim MS, Pinto SM, Getnet D, Nirujogi RS, Manda SS, Chaerkady R, Madugundu AK, Kelkar DS, Isserlin R, Jain S, Thomas JK, Muthusamy B, Leal-Rojas P, Kumar P, Sahasrabuddhe NA, Balakrishnan L, Advani J, George B, Renuse S, Selvan LD, Patil AH, Nanjappa V, Radhakrishnan A, Prasad S, Subbannayya T, Raju R, Kumar M, Sreenivasamurthy SK, Marimuthu A, Sathe GJ, Chavan S, Datta KK, Subbannayya Y, Sahu A, Yelamanchi SD, Jayaram S, Rajagopalan P, Sharma J, Murthy KR, Syed N, Goel R, Khan AA, Ahmad S, Dey G, Mudgal K, Chatterjee A, Huang TC, Zhong J, Wu X, Shaw PG, Freed D, Zahari M , Mukherjee KK, Shankar S, Mahadevan A, Lam H, Mitchell CJ, Shankar SK, Satishchandra P, Schroeder JT, Sirdeshmukh R, Maitra A, Leach SD, Drake CG, Halushka MK, Prasad TS, Hruban RH, Kerr CL, Bader GD, Iacobuzio-Donahue CA, Gowda H, Pandey A. A draft map of the human proteome. Nature, 509(7502), 575-581 (2014). [Pubmed]
Wu X, Zahari MS, Renuse S, Jacob HK, Sakamuri S, Singal M, Gabrielson E, Sukumar S, Pandey A. A breast cancer cell microarray (CMA) as a rapid method to characterize candidate biomarkers. Cancer Biol Ther., 15(12), 1593-1599 (2014). [Pubmed]
